Skip to main content

Site notifications

Notice for tozinameran (Pfizer Australia Pty Ltd)

Active ingredients
tozinameran
Date of review outcome
Lapse date
Type
Provisional determination
Indication
Active immunisation against COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 6 months to <5 years.
Therapeutic area
Infectious diseases

Help us improve the Therapeutic Goods Administration site